Abstract: A preparation for transdermal drug administration comprising a flexible backing layer and a pressure-sensitive adhesive layer containing a local anesthetic in a proportion of 40-65 weight %. Since the ratio of the amount of the undissolved local anesthetic (Ac) to that of the dissolved local anesthetic (As), Ac/As, in the pressure-sensitive adhesive layer is determined to be in the range of 0.1-1.8, the preparation for transdermal drug administration of the present invention is superior in self-adhesiveness and leaves no adhesive material upon removal from the skin. In addition, burst-like release of the undissolved drug from the pressure-sensitive adhesive layer immediately after application to the skin permits rapid appearance of the anesthetic effect, which enables wide clinical application of the preparations of the present invention.

Abstract: A dosage form is disclosed comprising a wall surrounding a compartment, which comprises a first composition comprising a carboxymethylcellulose and a second composition comprising a higher molecular weight carboxymethylcellulose. The first composition comprises a dosage amount of drug that delivers from the dosage form at a controlled rate over time.

Abstract: Hot-melt silicone pressure sensitive adhesive compositions containing alkylmethylsiloxane waxes, methods of using the compositions and devices made using the compositions are disclosed. The hot-melt silicone pressure sensitive adhesive compositions include a mixture of (i) a silicate resin, (ii) a silicone fluid, and (iii) an alkylmethylsiloxane wax having a melting point of between 30.degree. C. and 70.degree. C. The alkylmethylsiloxane wax decreases dynamic viscosity of the adhesive at temperatures ranging from about 50.degree. C. to about 200.degree. C.

Abstract: A method of increasing the adhesiveness of a shaped pressure sensitive adhesive, comprising adding an adhesiveness and drug release increasing amount of a clay to said adhesive prior to casting of the adhesive.A dermal composition comprising a drug, a pressure sensitive adhesive, an adhesiveness increasing amount of a clay and a solvent.A dermal composition comprising a drug, a multipolymer of ethylene vinyl acetate, an acrylic polymer, a natural or synthetic rubber and a clay, along with optional ingredients known for use in transdermal drug delivery systems.

Abstract: A percutaneous drug delivery method and enhancement composition are disclosed. The method comprises applying an enzyme preparation containing suitable amounts of non-enzyme permeation enhancers, such as lactam compounds (e.g. 1-substituted-azacycloheptan-2-one), and propylene glycol to a localized area of skin for a predetermined amount of time to enhance that area of skin's permeability to selected drug(s); occluding the area of skin during the application; and then applying the selected drug(s) to the area of skin to allow the drug to penetrate through the skin and into the circulatory system of the animal. Greatly enhanced penetration of chemicals through the skin results from the described treatment.

Abstract: An oral sustained release composition for slightly soluble pharmaceutically active agents comprising a core, a wall around said core, and a bore through said wall connecting said core and the environment outside of said wall; wherein said core comprises a slightly soluble active agent, optionally a crystal habit modifier, at least two osmotic driving agents, at least two different (or two different grades of) hydroxyalkyl celluloses, and optionally lubricants, wetting agents, and carriers; said wall being substantially impermeable to said core components and permeable to water and gastro-intestinal fluids. The composition is most especially adapted for administering carbamazepine.

Abstract: A dispenser is disclosed for delivering a beneficial agent in a hydrophilic carrier formulation to an animal in a rate-controlled manner. The dispenser comprises (1) a semipermeable housing defining an internal space, (2) at least one composition comprising a beneficial agent and a pharmaceutically acceptable hydrophilic carrier in the space, (3) an expandable hydrophilic driving member in the space, (4) a density member in the space, and (5) one exit passageway or a multiplicity of exit passageways in the housing for delivering the beneficial agent from the dispenser, the diameter of each exit passageway being of a size to maximize release of the beneficial agent by osmotic pumping and to minimize release of the beneficial agent by diffusion or erosion to substantially avoid mechanical agitation-dependent release of the beneficial agent.

Abstract: An agent for reducing the growth of human hair comprising a basic substance for application to the skin which contains a urea and demineralized, sterilized water.

Abstract: A transdermal delivery device has a reservoir containing an active compound, which is kept separate from the delivery layers of the device until administration. At the time of administration, the reservoir is laminated to the delivery layers, or is ruptured to place the active compound, vehicle, and/or permeation enhancers in contact with the delivery layers, which results in administration of the active compound to the skin after a delay period.

Abstract: This invention is directed to a non-invasive, topical treatment for telangiectasia, a dermatological condition commonly known as spider veins. The treatment preferably includes repeated applications of a composition having an effective amount of an inositol phosphoric acid or derivatives and mixtures thereof. Inositol hexaphosphate (phytic acid) is most preferred, with or without the use of a compression stocking.

Abstract: Polymer blends containing a very low density polyethylene copolymer of ethylene and 1-butene, 1-hexene, or 1-octene and about 15 to about 600 parts by weight of a linear low density polyethylene copolymer of ethylene and 1-octene, based on 100 parts by weight of the very low density polyethylene copolymer.

Abstract: The invention relates to a process for producing an administration and/or dosage form for medicament active substances using a printing process, in which the printing process used is a pad printing process.

Abstract: Oral pharmaceutical compositions in unit dosage form, especially capsules, comprising solid Colloidal Bismuth Subcitrate (CBS), optionally one or more auxilliary medicaments and excipients, the dosage units having a packing density of between 0.06 and 0.60 grams of CBS per ml.

Abstract: A percutaneous-administration-type pharmaceutical preparation of nitroglycerin is provided. The preparation comprises a backing that is impervious to medicines, and a pressure-sensitive adhesive layer that is placed on one surface of said backing, wherein said pressure-sensitive adhesive layer contains an alkyl (meth)acrylate (co)polymer in the concentration of 35-85% by weight, nitroglycerin in the concentration of 10-30% by weight, and a silicic acid anhydride in the concentration of 5-20% by weight, said (co)polymer contains as major (co)polymer components alkyl (meth)acrylates with alkyl groups having 6 or more carbon atoms, which alkyl (meth)acrylates include 2-ethylhexyl methacrylate in the concentration of 40-100% by weight based on the total weight of said alkyl (meth)acrylates. The preparation makes it possible for nitroglycerin to be absorbed percutaneously at a controlled rate for a long period of time. Also, even a compact preparation can supply a sufficient amount of nitroglycerin.

Abstract: A matrix for containing drugs for transdermal delivery systems is disclosed. The matrix, formed of a skin-adhesive acrylate copolymer, attains high rates of drug delivery without the addition of drug delivery rate enhancers. In preferred embodiments the matrix is used to administer steroids, in particular estradiol. Water-soluble polymers may be added as well.

Abstract: A method of administering 3'-azide-3'-deoxythymidine (AZT) to an AIDS patient who is in need of treatment with AZT, comprising applying AZT to the skin of said patient together with an absorption promoting agent capable of assisting absorption of AZT through the skin into the blood stream of said patient; and a percutaneous composition comprising AZT as an effective Ingredient together with an absorption promoting agent in an amount effective for assisting percutaneous absorption of AZT.

Abstract: The invention deals with devices, in particular with bandage strips, for a transdermal delivery of drugs to patients, whereby the drug formulations include highly viscous preparations, topical solutions of a low viscosity and micro-emulsions of a low viscosity containing the drugs. Depending on the consistency of the medium containing the drug, the drug formulation is stored in a reservoir, consisting, e.g., of a punched out cavity or of an absorbent piece of material, which is encased or supported by a carrier element (a foamed material piece or a non-woven fleece tape) adhering to the skin by means of a skin-compatible adhesive, whereby specially formed protective films are applied at the filling and delivery side during the storage of the device to prevent a lateral migration, and whereby during its use, the device can be refilled with dosed amounts by the patient without requiring a removal of the device from the skin surface to be treated (FIG. 2).

Abstract: The present invention is directed to a long-term dispensing device for the controlled delivery of a beneficial agent in a hydrophilic carrier, which device quickly and continuously delivers an effective amount of agent followed by a continuous and sustained delivery of agent in a controlled and uniform amount over a prolonged period of time, thus providing for delivery of beneficial agent to an environment of use at two different rates and having a fast startup.

Abstract: The controlled release of buprenorphine or the pharmaceutically acceptable salts thereof to the skin over a period of time of at least 24 hours is ensured by a transdermal therapeutic system consisting of a backing layer which is impermeable to the active substance, a pressure-sensitive adhesive reservoir layer, and optionally a removable protective layer. Said reservoir layer of said system comprises 20 to 90%-wt polymeric material, 0.1 to 30%-wt softener, 0.1 to 20%-wt buprenorphine base or one of the pharmaceutically acceptable salts thereof, and 0.1 to 30%-wt solvent for the active substance base.

Abstract: Skin permeation enhancer compositions are provided which increase the permeability of skin to transdermally administered pharmacologically active agents. The compositions contain a lower aliphatic ester of a lower aliphatic carboxylic acid such as ethyl acetate and a lower alkanol such as propylene glycol. Methods and transdermal drug delivery systems for using the compositions are also provided.